Basic Information
| LncRNA/CircRNA Name | AB209630 |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | gemcitabine | |
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | pancreatic cancer |
| ICD-0-3 | C25 |
| Methods | qRT-PCR etc. |
| Sample | pancreatic cancer tissues ,human pancreatic cancer cell line CFPAC-1 ,Human normal pancreatic cell line hTERT-HPNE |
| Expression Pattern | up-regulated |
| Function Description | QYHJ, especially the combination of GEM and QYHJ, was significantly inhibited the cell proliferation and migration of CFPAC-1 in vitro in the indicated times. The combination of GEM and QYHJ also remarkably promoted the cell apoptosis of CFPAC-1.QYHJ treatment effectively blocked the tumor growth in nude mice.QYHJ, especially GEM + QYHJ treatment, was significantly increased the mRNA expression of lncRNA AB209630, significantly decreased the mRNA levels of miR373, EphB2 and NANOG, and markedly reduced the tumor sphere formation and the numbers of CD133+ stem cells. |
| Pubmed ID | 31147453 |
| Year | 2019 |
| Title | Qingyihuaji Formula Reverses Gemcitabine Resistant Human Pancreatic Cancer Through Regulate lncRNA AB209630/miR-373/EphB2-NANOG Signals |
External Links
| Links for AB209630 | GenBank HGNC NONCODE |
| Links for pancreatic cancer | OMIM COSMIC |